XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Segment Information
11. SEGMENT INFORMATION

Information regarding net sales and operating profit (loss) for the three months ended September 30, 2024 and 2023 are as follows (in millions):

Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2024$260.9 $388.8 $— 
 2023$263.5 $368.1 $0.5 
Operating profit (loss)2024$(9.8)$74.2 $0.1 
 2023$13.0 $78.0 $(0.1)

Information regarding Net sales and operating profit (loss) for the nine months ended September 30, 2024 and 2023 are as follows (in millions):

Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2024$753.1 $1,145.4 $0.5 
 2023$887.3 $1,100.3 $2.5 
Operating profit (loss)2024$1.1 $209.9 $(0.3)
 2023$76.7 $166.1 $(0.3)

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Our CODM views all operating expenses and corporate overhead as directly supporting the strategies of our segments, and these costs are fully allocated to our reportable segments.
The following reconciles total operating profit to consolidated income (loss) before income taxes (in millions):

Three Months EndedNine Months Ended
September 30,September 30,
 2024202320242023
Operating profit$64.5 $90.9 $210.7 $242.5 
Interest expense(12.2)(12.3)(36.7)(37.2)
Foreign currency exchange (losses) gains, net
(1.6)1.7 2.0 5.3 
Gains (losses) from change in fair market value of equity securities and loan receivable
792.8 36.4 (1,680.3)(1,576.5)
Other income, net18.1 20.4 70.7 87.4 
Consolidated income (loss) before income taxes
$861.6 $137.1 $(1,433.6)$(1,278.5)